ArticleCancers2023

COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma.

Carola Berking et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.